2,401 results on '"Müller-Tidow, Carsten"'
Search Results
2. The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance
3. CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
4. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols
5. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
6. Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance
7. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
8. DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts
9. Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities
10. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
11. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
12. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
13. The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations
14. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
15. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
16. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
17. Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy
18. Human and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts
19. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
20. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
21. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
22. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
23. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
24. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
25. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
26. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
27. Targeted siRNA nanocarrier: a platform technology for cancer treatment
28. The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia
29. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
30. Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia
31. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature
32. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study
33. Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
34. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
35. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
36. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
37. Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies
38. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
39. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia
40. Physical biomarkers for human hematopoietic stem and progenitor cells
41. Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia
42. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
43. Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
44. Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation
45. Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome
46. Overlapping features of therapy-related and de novo NPM1-mutated AML
47. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
48. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
49. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML
50. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.